近日,FDA批准Imbruvica(Ibrutinib)用于治疗套细胞淋巴瘤(MCL)。MCL是一种罕见的非霍奇金淋巴瘤,其发病率约占美国所有非霍奇金淋巴瘤病例的6%。通常MCL确诊时,肿瘤细胞已扩散至淋巴结、骨髓和其他器官。本品适用于既往至少接受过一次治疗的MCL患者,本品主要通过抑制肿瘤细胞增殖与扩散所需酶发挥治疗作用。本品是第三种获批用于治疗MCL的药品。此前,万珂(Velcade,2006)与来那度胺(Revlimid,2013)也获批用于治疗该病症。 Recently, FDA approved Imbruvica (Ibrutinib) for the treatment of mantle cell lymphoma (MCL). MCL is a rare non-Hodgkin's lymphoma whose incidence accounts for about 6% of all non-Hodgkin's lymphoma cases in the United States. Often when the MCL is diagnosed, tumor cells have spread to lymph nodes, bone marrow and other organs. This product is suitable for at least once treated MCL patients, this product mainly through the inhibition of tumor cell proliferation and proliferation of enzymes needed to play a therapeutic role. This product is the third approved for the treatment of MCL drugs. Previously, Velcade (2006) and Revlimid (2013) were also approved for the treatment of this condition.